Concepedia

James R. Woodworth

JR

Statistics

Publications

32

Citations

2.4K

H-Index

22

Active since

1982

Affiliations

Eli Lilly (United States)(Current)

Sidney & Lois Eskenazi Hospital

Biogen (United States)

The University of Texas MD Anderson Cancer Center

United States Army Institute of Surgical Research

James R. Woodworth is an author at Eli Lilly (United States) specializing in pharmacology, pharmacokinetics, and pharmacy.

Publications per year

1982–2021

32

Publications

32

[Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin

Daniel C. Howey, Ronald R. Bowsher, Rocco L. Brunelle et al. · Diabetes · 1994 · 451 citations

, , +13

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

Bhupendra Khatri, S. Man, Gavin Giovannoni et al. · Neurology · 2009 · 280 citations · Full text

, , +17

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation

David Rinaldi, John G. Kuhn, Howard A. Burris et al. · Cancer Chemotherapy and Pharmacology · 1999 · 175 citations

, , +12

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

James R. Woodworth, Eldon H. Nyhart, Gordon Brier et al. · Antimicrobial Agents and Chemotherapy · 1992 · 158 citations

, , +8

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

David Rinaldi, Howard A. Burris, F. Andrew Dorr et al. · Journal of Clinical Oncology · 1995 · 152 citations

, , +17

1–5 of 32